Please ensure Javascript is enabled for purposes of website accessibility

Mettler Toledo International Inc (MTD) Q4 2020 Earnings Call Transcript

By Motley Fool Transcribers - Feb 5, 2021 at 1:01AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

MTD earnings call for the period ending December 31, 2020.

Logo of jester cap with thought bubble.

Image source: The Motley Fool.

Mettler Toledo International Inc (MTD 4.67%)
Q4 2020 Earnings Call
Feb 4, 2021, 5:00 p.m. ET

Contents:

  • Prepared Remarks
  • Questions and Answers
  • Call Participants

Prepared Remarks:

Operator

Ladies and gentlemen, thank you for standing by and welcome to the Quarterly Earnings Conference Call. [Operator Instructions]

I would now like to hand the conference over to your speaker for today, Ms. Mary Finnegan. Thank you, ma'am. Please go ahead.

Mary T. Finnegan -- Head of Investor Relations

Thanks. Catherine, and good evening everyone. I'm Mary Finnegan. I'm responsible for Investor Relations at Mettler Toledo and happy that you're joining us tonight. I'm joined on the call today with Olivier Filliol, our CEO and Shawn Vadala, our Chief Financial Officer. Let me cover just a couple of administrative matters.

This call is being webcast and is available for replay on our website. A copy of the press release and the presentation that we refer to on today's call is also available on our website. Let me summarize the safe harbor language which is outlined on Page 2 of the presentation. Statements in this presentation, which are not historical facts constitute forward-looking statements within the meaning of the U.S. Securities Act of 1933 and the U.S. Securities Exchange Act of 1934. These statements involve risks, uncertainties, and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from those expressed or implied by any forward-looking statements.

For a discussion of these risks and uncertainties, please see our most recent Form 10-K and other reports filed with the SEC from time to time. All forward-looking statements are qualified in their entirety by reference to the factors discussed under the caption Factors Affecting Our Future Operating Results and in the Business and Management Discussion and Analysis of Financial Condition and Results of Operations sections of our filings.

Just one other item, on today's call, we may use non-GAAP financial measures. More detailed information with the respect to the use of and differences between the non-GAAP financial measure and the most directly comparable GAAP measure is provided in our Form 8-K.

I will now turn the call over to Olivier.

Olivier A. Filliol -- Chief Executive Officer

Thank you, Mary and good evening everyone. I'm calling in from Switzerland tonight, while Shawn and Mary are in Columbus, Ohio. Patrick Kaltenbach is also joining the call with me from Switzerland and we are excited to have him on board. Patrick and I have had very productive on boarding sessions over the last few weeks and he most recently has begun to meet with the senior leadership team who is very happy to welcome him.

Patrick, I will turn it to you as I know you want to make a few comment.

Patrick Kaltenbach -- Chief Executive Officer Designate

Thanks Olivier and good evening everyone. I am very happy to join this call tonight and more importantly to be part of Mettler Toledo. I spent my time so far, working with Olivier, meeting senior leaders virtually throughout the world, and studying thorough strategy documents, comprehensive materials on Spinnaker approaches and detailed R&D and SternDrive priorities.

I'm truly impressed with the depth and sophistication of the strategy, initiatives and programs that are in place. A fantastic foundation has been built and I'm committed to the organic growth strategy and look forward to leading a team to further enhance our performance and continue the successful journey. Olivier and Shawn will lead this

Call today and I look forward to the actions on the next call and in the future.

Before I hand it back. I want to make a personal thank you to Olivier for the excellent on-boarding process and for handling -- handing over to me such a unique franchise. Under your leadership, you have developed Mettler Toledo into a tool with a tremendous track record and future potential. I'm very pleased to note that you will continue to be part of the company.

Olivier, I will turn it back to you. Now thank you, Patrick. For this very kind words. From my side, we are off to a great start and I look forward to our continued teamwork. I will start with a summary of the quarter and then, Shawn will provide details on our financials. I will then have some additional comments and we will open the lines for Q&A. The highlights for the quarter are on Page 3 of the presentation. We ended the year with a very strong fourth quarter, which came in better than we expected. Local currency sales increased 7% in the quarter, our growth was relatively broad-based throughout the world. Our Laboratory business and our Chinese business did particularly well in the quarter. We benefited from strong execution and we're well-positioned to capture growth as customer demand improved. However, we continued to be negatively impacted by COVID-19 in certain areas. From the onset of the global pandemic, our focus has been to identify and pursue pockets of growth within our end markets and to be well-positioned to capture growth as demand improves, which is what we saw in Q4. Our innovative go-to-market approach really played very well into this environment and allowed us to capture this growth. Good cost control and the continued benefit of our margin and productivity initiatives contributed to strong growth in adjusted operating profit and very strong growth in adjusted EPS in the quarter. Finally, cash flow not one in the quarter, but also for the full year was excellent. 2020 was an extraordinary year with some of the most challenging market conditions we have faced in more than a decade. Our organizational agility helped us to quickly adapt approaches and processes to the new environment. Our broad end-market diversification and the use of sophisticated data analytics allowed us to shift our sales and marketing focus to the most promising end markets early on. It also helps to ensure we were well-positioned to capture growth as demand improved during the latter part of the year. We adopted our supply chain and service organization to maintain superior performance that strengthened our franchise and introduced many new digital sales and support tools to provides top quality customer interactions despite the remote settings of our customers and sales teams. Throughout 2020, we increased our customer engagement and customer satisfaction, which translated into accelerated market share gains in many product categories. With the strong ends to 2020, we have very good momentum as we start 2021, and believe we are well-positioned to continue to gain share and deliver good results. We will have some additional comments on 2021 but first, let me turn to Shawn to cover the financial results.

Shawn Vadala -- Chief Financial Officer

Thanks, Olivier, and hello everyone. Sales were $938 million in the quarter, an increase of 7% in local currency. On the U.S. dollar basis, sales increased 11% as currency benefited sales by 4% in the quarter.

On Slide number 4, we show sales growth by region. Local currency sales increased 8% in the Americas, 7% in Europe, and 8% in Asia, rest of the world. Local currency sales increased 12% in China in the quarter. The next slide shows sales growth by region for the full year 2020. Local currency sales increased 2% in the Americas, 1% in Europe and 3% in Asia/rest of the world. China local currency sales grew 7% in 2020.

On Slide number 6, we outlined local currency sales growth by product area. For the fourth quarter laboratory sales increased 12%, industrial increased 1%, with core industrial up 5%, and product Inspection down 5%. Food Retail increased 7% in the quarter. We estimate that we benefited 1% to 2% from COVID tailwinds in the quarter related to our pipette business for covered testing. The next slide shows sales growth by product area for the full year. Laboratory sales increased 5%, industrial declined 1% with core industrial up 2%, and Product Inspection down 7%. Food Retail declined 4% in 2020.

Let me now move to the rest of the P&L for the fourth quarter, which is summarized on the next slide. Gross margin in the quarter was 59.6%, a 60 basis point increase over the prior-year level of 59%. Our margin initiatives centered on pricing in SternDrive, as well as temporary cost savings contributed to the margin growth, offset in part by higher transportation costs and unfavorable business mix.

R&D amounted to $39.9 million, which represents a 6% increase in local currency. SG&A, amounted to $226.4 million, a 5% increase in local currency over the previous year. Increased variable compensation was offset in part by our temporary cost savings and ongoing cost containment initiatives. Adjusted operating profit amounted to $292.8 million in the quarter, which is a 14% increase over the prior year amount of $256.3 million. Operating margins increased 80 basis points in the quarter to 31.2%. We are very pleased with this margin growth. Currency benefited operating profit growth by approximately 2%, but actually hurt operating margin expansion by about 50 basis points.

A couple of final comments on the P&L. Amortization amounted to $14.7 million in the quarter. Interest expense was $9.5 million in the quarter and other income amounted to $3.7 million. We reduced our effective tax rate for the full year from 20.5% to 19.5%. This is the rate before discrete items and adjusting for the timing of the stock option exercises in the quarter. We are very pleased with this reduction and expect to maintain this rate in 2021.

Moving to fully diluted shares, which amounted to $24 million in the quarter and is a 3% decline from the prior year. Adjusted EPS for the quarter was $9.26, a 19% increase over the prior year amount of $7.78. Currency benefited adjusted EPS by approximately 2% in the quarter. On a reported basis in the quarter, EPS was $9.03 as compared to $7.84 in the prior year. Reported EPS in the quarter includes $0.12 of purchased intangible amortization and $0.11 of restructuring.

We also had 2 offsetting items for income taxes. We had a $0.20 increase due to the difference between our quarterly and annual tax rate due to the timing of stock option exercises. This was offset by a $0.20 benefit from adjusting our tax rate to 19.5% for the first three quarters.

The next slide shows our full year results. Local currency sales increased 2% in 2020 while adjusted operating income increased 8% and adjusted operating margins were up 130 basis points. Adjusted EPS amounted to $25.72, an increase of 13% over the prior year amount of $22.77. Currency was neutral to the full year adjusted EPS. Given the unprecedented challenges we faced in 2020, we are very pleased with our performance and believes it reflects the agility and the strong culture of our organization, the effectiveness of our growth in margin expansion initiatives, in resiliency of our end markets. That is it for the P&L.

Now let me cover the cash flow. In the quarter, adjusted free cash flow amounted to $218 million, which is an increase of 20% on a per share basis, as compared to the prior year. We are very happy with our cash flow generation. DSO declined approximately 3.5 days in the quarter to 36.5 days as compared to the prior year. We are seeing concrete results from the use of analytics and productivity improvements in receivable collections and cash flow management during this period.

ITO came in at 4.3 times. For the full year 2020, adjusted free cash flow was $648 million as compared to the prior year amount of $531 million. On a per share basis, this is a 26% increase in earnings flow-through of more than 100%. We are very pleased with this performance, which demonstrates the strength of our franchise as well as our focus on continuous process improvements to drive cash flow generation.

Let me now turn to guidance. Forecasting continues to be challenging given the uncertainty surrounding Covid-19 and the ultimate impact for the global economy. Market dynamics are fluid and changes in customer demand can happen quickly. With our strong fourth quarter performance, we continue to feel confident about those factors within our control, namely executing on our sales and marketing initiatives, and continuing to launch new products with clear value-added benefits to our customers.

We believe we have been successful in identifying and capitalizing on pockets of growth and are well positioned to continue to gain share. We also continue to feel positive in our ability to generate margin improvement by our pricing and SternDrive initiatives.

Now let me cover the specifics. For the full year 2021, we now expect local currency sales growth will be in the range of 5% to 7% as compared to 2020. We expect full year adjusted EPS will be in the range of $29.20 to $29.80, which is a growth rate of 14% to 16%. This compares to previous adjusted EPS guidance in the range of $27.50 to $28.30. With respect to the first quarter, we would expect local currency sales growth to be in the range of 11% to 13% and expected adjusted EPS to be in the range of $5.55 to $5.70, a growth rate of 39% to 43%.

Some further comments on 2021 guidance. Let me start with the pacing of the year. We expect the first half of the year will be much stronger than the second half. We are starting the year with excellent momentum coming off a strong Q4. The first half of the year will also benefit from easier comparisons and the continued tail -- Covid tailwind in our pipette business. As we look to the second half, we will face more difficult comparisons, particularly with respect to our business in China.

Our Covid tailwinds will also turn to a headwind as we lack comparisons. We also feel more uncertainty exists for the second half of the year, especially with respect to Covid's potential impact to the global economy. We recognize that we're currently benefiting from strong momentum, which will not necessarily continue. We will provide additional quarterly guidance on our next call, but I thought it would be helpful to provide this context now.

Some additional comments on guidance. We expect interest expense to be approximately $40 million in 2021 and total amortization to be approximately $55 million. Other income, which is below operating profit, will be approximately $9 million in 2021. As I mentioned earlier, we would expect our effective tax rate in 2021 to also remain at 19.5%. In terms of free cash flow for the year, we expect it to be approximately $690 million. We will continue to repurchase shares and expect to end 2021 in a targeted range of approximately 1.5 times leverage ratio.

Some additional details. With respect to the impact of currency on sales growth, we expect currency to increase sales growth by approximately 3.5% in 2021 and 5% in the first quarter. In terms of adjusted EPS, currency will benefit growth by approximately 3% in 2021. That is it from my side, and I'll now turn it back to Olivier.

Olivier A. Filliol -- Chief Executive Officer

Thank you, Shawn. Let me start with some comments on our operating results. Our Lab business have exceptional growth in the quarter. Pipettes have excellent growth and benefited from COVID-related testing demand. Process Analytics had another quarter of strong growth, while demand for analytical instruments and balances recovered nicely in the quarter. Sales growth in all regions was very strong. We expect Lab to continue to be very strong in the first half of 2021 due to favorable biopharma trends, vaccine research, and testing a bioproduction scale-up and production.

Lab will face tougher comparisons in the second half of the year. With our excellent Lab product portfolio including our power demand solutions, focus on automation, digital interfaces and data management and prove -- proven Spinnaker sales and marketing strategies, we believe we are well positioned to continue to capture share. In terms of Industrial business, Core Industrial did well in the quarter with a 5% increase driven by double-digit growth in China.

We will return to growth in Core Industrial in Europe, while Americas was flat, although they have very good growth in the prior year. We are particularly pleased at how resilient our Core Industrial has proven throughout 2020 given the challenges of the pandemic. We believe this reflects the strength and diversity of our product portfolio, our success in identifying on pursuing pockets of growth, and strong focus on execution. Our outlook for Core Industrial remains solid, but we acknowledge, we are not immune to the overall economy and we will face difficult comparisons in China during the second half of the year.

Product Inspection came in weaker than we had anticipated with a 5% decline in the quarter. Both Europe and Asia declined while Americas was flat with the prior year. While our outlook has improved for this business and we expect to start 2021 with solid growth, we are cautious as large package food companies continue to face operational challenges at their manufacturing sites related to COVID. We believe pent-up demand exists for our instruments but ultimate timing is still hard to determine. Food retailing came in better than we expected with 7% growth overall and growth in all regions.

Now let me make some additional comments by geography. Sales in Europe increased 7% in the quarter with excellent growth in Lab and good growth in core industrial and food retail. We expect solid growth in Europe in 2021. Americas increased 8% in the quarter with excellent growth in Lab offset by flat results in both product inspection and core industrial. We expect good growth in Americas in 2021. Finally, Asia/Rest of the World grew 8% in the quarter with both Lab and Core Industrial doing very well. As mentioned, China have 12% growth in the quarter with excellent growth across product lines. We expect market conditions in China to be very favorable as we start 2021 while they face much tougher comparisons in the second half of the year.

One final comment on the business, Service and Consumables were up 13% in the quarter and 8% for the full year. That concludes my comments on the business. As I reflect on 2020. I'm very pleased with our performance given the exceptional challenges we faced. This performance would not have been possible without the strong foundation and well-ingrained corporate programs that we have in place, which allowed us to quickly pivot and adapt to the new environment.

We have always considered agility and focus on execution a key pillar of Mettler-Toledo and I think you saw evidence of both of these in our results. Probably most important, however, our success in 2020 sets the stage for us to continue to capture growth in 2021 and beyond. Our strategy over many years has been remarkably consistent. As a leader in fragmented market, we have established strategies that allow us to gain a little market share each year while continuously expanding our margin. The initiatives within these strategies will involve and develop but strategies remain the same.

As we look to 2021, let me comment on how we are going about this. I would start with our Spinnaker sales and marketing initiatives. As we discussed on our last call, we made some leapfrog advances in digital transformation during 2020 that positioned us very well for the future. We will continue to refine our sophisticated Analytics to guide our sales force to the best opportunities. We will continue to support our market organization with tools and methodologies to increase sales force time with the most strategic account while leveraging our value-selling and cross-selling tools to further penetrate opportunities. We will also continue to leverage digitalization to develop new approaches that drives sales force efficiency and refine techniques to improve the effectiveness of telesales team, but also look forward to returning to visit accounts to generate new opportunities.

Finally, we look to execute more telemarketing campaigns, enhance tools to increase order conversions. Service will continue to be essential element of our customer value proposition. Our almost 3,000 service technicians are an important competitive advantage for us. This year, we will focus on further I base penetration and utilizing many of the same sales force guidance telesales of digital tools that we use for product sales to further drive service sales.

Our team in China did an exceptional job in 2020, not only continuing to serve customers and penetrate growth opportunities, but also in terms of manufacturing and supply chain. The team's priorities to continue to optimize the organization to focus on high potential growth areas and attractive segment and further leverage digital technology to engage customers and generate leads.

Introducing products for the local market such as an entry-level x-ray instrument for our product inspection portfolio is also an important element to growth in China and throughout emerging markets. We remain very optimistic about the growth potential, not one in China, but throughout emerging markets over the medium term.

Constantly coming to market with new product launches is another important strategy. Given the diversification of our product portfolio, a new product launch will never be material by itself, but together, these launches reinforces our market leadership, help trigger replacement in existing customers, help open doors to new customers, and help support our price differentiation. Later this month, we will launch a new automatic laboratory balance that will set a new standard for weighing of powders and liquids in research labs, testing labs and quality-control labs.

Addressing the needs in the Laboratory for automation, smaller sample sizes, flexibility, ease of use, and seamless documentation, this new balances offers an unmatched value proposition. It is a simple fully integrated solution that will support our customers in their everyday operation. It is just one example of the many product launches we will have this year, but illustrates how we are continually focused on bringing products to market that demonstrate clear value to our customers.

Similar to the continued evolution of growth strategies, we also continue to develop our pricing and productivity initiatives. We have good results -- good developments within pricing, utilizing Analytics, and so machine learning to most effectively price our offering. On the supply chain side, the team was able to continue to make progress on their SternDrive productivity goals in 2020, but we will be able to make further progress in 2021 when the team won't have as many challenges as they faced last year.

Finally, I think you will continue to see us market strategic acquisition that leverage our technology leadership and global distribution. I acknowledge that we have not had an acquisition for a while, but continue to believe which are benefited from acquisition. However, these acquisitions will be small and strategic, not transformational. I believe our franchise is stronger than ever as demonstrated in how we performed in 2020 despite all the challenges. As I look back over the last decade plus years, we have made much progress in many areas. Our continuous improvement programs of Spinnaker, sales and marketing, and SternDrive productivity, which I just discussed, are well ingrained throughout our organization and we'll continue to evolve and be important ingredients for the future.

Emerging markets, an important growth driver are 35% of sales today compared with 25% in 2007. Similarly, our faster growing Laboratory business is now 54% of sales, up from 44%. Finally, Service and Consumable is now 33% of sales as compared to 28%. Redirecting resources and investments to faster growing businesses has always been at the heart of our initiatives and these businesses will continue to fuel growth in the future. The strength of the organization and how well we are positioned for the future contributed to my decision to step down as CEO. Under Patrick's leadership, I believe we have the organization, corporate programs, senior leadership team, and tools in place to continue to gain share and continue our successful track record.

That concludes our prepared remarks. Now I want to open the line for questions.

Questions and Answers:

Operator

[Operator Instructions] Your first question comes from the line of Tycho Peterson with JPMorgan.

Tycho Peterson -- JPMorgan -- Analyst

Hey, thanks. Olivier. I know you have one more quarter so we won't congratulate you on the transition just yet, but maybe, thinking about the Service and Consumable numbers you highlighted, sales up 30%, can you maybe just talk about the durability, how much of that was pent up versus maybe some of the newer initiatives, especially on the service side?

Olivier A. Filliol -- Chief Executive Officer

Yeah. So we would estimate that the COVID tailwind was about 1% to 2% for the Group, and that was really related to the consumer business mainly or almost exclusively around pips that we produce in our reigning biotechs facility. So that was actually really strong. But then the remainder of the service and consumable business was healthy and quite sustainable. I was actually pleased to see how we continued to perform service well even under, again, more difficult lockdown situations, particular, also in Europe, started end of Q4, and nevertheless our service business could nicely hold up. And I would expect the same for this year. So I would almost say for our service business, we have a healthy environment and I continue to expect similar growth as we had in the past.

Tycho Peterson -- JPMorgan -- Analyst

Okay, that's helpful and then product Inspection. I know you've been talking about pent-up demand with the other CPG customers for a while. Obviously, we are not seeing it yet. Maybe talk a little bit about what you're hearing in that channel?

Olivier A. Filliol -- Chief Executive Officer

Yes. So indeed, we still see good demand for quotes. We feel we have a very good market position. But we see that customers are just not committing to upgrades and new packaging lines and so on, which is not surprising. All these food companies really need to protect the protection -- protect their production from any COVID exposures, and you can imagine they have very rigid safety procedures, not wanting to let in any external suppliers and that really drives the demand.

And I wouldn't be surprised if this takes and all the 6 months, there are many production companies here that really hold back on capex and as a reminder about more than 70% of our revenue in Product Inspection is coming from food production. So yes, we count on the second half that we would really see a strong pent-up demand, but I do expect that already Q1, we will see better numbers, but not necessarily coming from pent-up.

Tycho Peterson -- JPMorgan -- Analyst

Okay and then lastly on China. Last quarter, you talked about some pull forward, you still had good growth, 12% overall industrial up double digits. Maybe just talk a little bit about the sustainability, and then if you could quantify what is baked into the guidance for China growth this year.

Olivier A. Filliol -- Chief Executive Officer

Yeah, so let me take the first part and regarding the specific then Shawn can add in. Yeah, indeed we are very happy about how Q4 came together. The Chinese team did perform really, really well. And there is also a good market for us. We see that the Chinese local investment is going very well we benefit from that. The investments also go in the right market segments for us that we can benefit from. And I would certainly expect that this momentum will still go on those, for a while, we have here for first half of Q1, I still have good expectations.

For the second part of the year, however, we got our face tougher comparisons and that's certainly one of the reasons why we guide, when it comes to China, a good start, but then a slowdown in the second part of the year now. Now, Shawn, do you want to add some flavor to that last comment?

Shawn Vadala -- Chief Financial Officer

Yes, sure. Thanks, Olivier. and hi, Tycho. Yes, so for the full year in China, Tycho, we're now looking at high single-digit growth for the full year. That's a improvement from our previous guidance where we were saying mid-single digit. And right now we're feeling that that high single-digit would be both in the laboratory and the industrial business, but as Olivier mentioned on the pacing its going to be pretty unique just giving the whole situation with the comparison in Q1 of last year and then when we look at the second half of last year as well. So just to be even a little bit more specific on that, in Q1, we're going to -- we expect China to be up mid to high 20s in terms of growth, but again that was versus a minus 13% in Q1 of last year. And then of course we're going to have to lap some of these tougher comparisons, which included 17% growth in Q3 of last year and now 12% in Q4 of this year.

Tycho Peterson -- JPMorgan -- Analyst

Okay, thank you.

Shawn Vadala -- Chief Financial Officer

Yes.

Operator

Our next question comes from the line of Derik De Bruin with Bank of America. Hi, good afternoon. How are you doing?

Shawn Vadala -- Chief Financial Officer

Yes. Hey, Derek.

Derik de Bruin -- Bank America -- Analyst

Hey. So I just -- first question is how did price income through in 2020 and just curious if you've got better pricing than normal, given the huge demand for pipettes and just if you took some price advantage there, and just sort of like what are you expecting in the '21 numbers for pricing?

Shawn Vadala -- Chief Financial Officer

Yes, so -- hey, Derek. I'll take it, Shawn. So we did -- so in the fourth quarter, we did just under 2.5% in terms of price realization. So that was a little bit of an improvement from what we were seeing earlier in the year. I think each quarter, we started to see things progressively get a little bit better. Part of that improvement was that we were able to take a little bit more price on in the area of pipettes, as you just mentioned. We also were able to do a couple of other things where we're trying to offset some of these higher transportation costs, as well. As we look to 2021, we were previously guiding a little bit more cautiously in the 150 basis point kind of a range, with the concern that inflationary forecasts, a few months ago were quite low for 2021, but still feel extremely good about the momentum in the program. Olivier also alluded to a few of those things in the prepared remarks as well. At this point in time, we're looking at probably a range of 150-200, wouldn't be surprised if we were more toward the higher end of that range as we kind of see some of the dynamics in the market, we do see some opportunities to maybe -- to gain a little bit more price than we saw maybe a few months ago. And we'll see how that plays out, but that's certainly something on our mind right now. Of course the other side of that is that some of these opportunities and price are also looking at higher material costs in certain areas that we are mindful of that we might be facing as well too.

Derik de Bruin -- Bank America -- Analyst

Great, that's really helpful. And, Olivier, you made an interesting comment in the opening remarks. Just talking about accelerating market share gains in many categories. Can you give us a little bit more color on that?

Olivier A. Filliol -- Chief Executive Officer

Yes. Like always, we -- it's difficult to have hard data on that. Our competitors do not publish specific comparable numbers, and so we need to base this on the observation of our field force. We certainly also observe it kind of the growth momentum we see in the different industry segments and what we can expect and based on that we feel actually really good. We have also clear anecdotes that we are winning share and I feel we are outpacing the market we have this MGDP benchmark, and I certainly feel that we are outpacing that. And so that gives us all this confidence of this share gain. There are some other data points that we use internally. I mentioned that we leverage data analytics to guide our sales force. Last year we had a special effort to guide the sales force to non-customers. We did so because suddenly our sales force spent much less time behind the wheel. They had much more time doing cold calling and engaging new customers through virtual day modes and virtual calls and that was at the base for us to expand the targets through our sales force and we were very pleased to see the results in converting more than ever non-customers. So that that gives us kind of the confidence that this allows us to win share. So in a nutshell, we feel that we protected well our existing customer base while we accelerated the access of the conversion to non-customers, certainly, a strategy that we're going to pursue. I many times said the crisis last year was for us an opportunity to leapfrog some of the changes, in terms of go-to-market, leapfrog the adaptation of internal new tools and techniques and one of them was simply all about the sales force guidance and reaching out to non-customers. We are going to certainly maintain that one.

Derik de Bruin -- Bank America -- Analyst

Great, thanks for the detail.

Operator

Your next question comes from the line of Vijay Kumar with Evercore ISI.

Vijay Kumar -- Evercore ISI -- Analyst

Hey guys. Congrats on a nice print here. Olivier, maybe I'll start with a high-level question for you. The guidance here 5 to 7, it's a pretty solid guide. What is it assuming from a business environment perspective, like are you assuming the environment is back to normal or is there some cushion for a perhaps disruption from second wave and then your comments on M&A, you felt like a tone change. I'm curious if we read that the right way. Is that a change in tone?

Olivier A. Filliol -- Chief Executive Officer

Let me take the first. Okay. We assume a relatively stable environment in terms of second wave. In Europe, we are in the middle of the second wave. We are definitely on quite a strict lockdown in many of the countries, started already before Christmas. It feels very different to the first lockdown, the business while we or many of us are in home offices, we have here an infrastructure and an understanding with our customer base that business is going on. We definitely leverage all these. We have also less customer visits, but effective relationships and we do not see that the core customer base is putting investments on hold. So that's why this second wave is very different to the first wave when it comes to the business impact.

On personal levels, it feels kind of similar, but not on a business level. I -- if the environment stays about what it is right now, that's probably our base for our guidance here, I am not particularly worried that the lock-down situation will significantly impact our business. And that means if the lockdown gets more severe or if everything would suddenly ease up, it looks like we have built here a certain resilience in our own business approach as well as the business or the industry segments that we are targeting. I want also to remind, we did quite a shift last year in terms of the industry segments that we are targeting and that shift we're going to maintain.

Don't beat too much around the M&A language. It's really in the sense that reinforcement of the strategy that we have been running in the past. We are very interested in adjacencies. We are interested in companies that fit well in our current business full course and my point was even that we have here leadership transition. Patrick and I share a common understanding here that we don't need any transformational acquisitions. We are not seeking any additional lag to the company. We feel we have an excellent franchise, that we want to leverage the franchise when there are good opportunities out there, again, technology, synergies or selected market consolidation opportunities. These are the typical adjacency that we did in the past and that we are certainly going to continue to pursue.

Vijay Kumar -- Evercore ISI -- Analyst

I understood. And, Shawn, one quick one for you. On the margins, looks like the margin guidance, it's implied it's gone up versus the prior guide. Is that a fair statement?

Shawn Vadala -- Chief Financial Officer

I'm sorry, Vijay. Can you repeat that question?

Vijay Kumar -- Evercore ISI -- Analyst

On the margin guidance, it seems versus your prior expectations in a margin expansion, perhaps is closer to triple digits, at the high end of the guidance, is that correct.

Shawn Vadala -- Chief Financial Officer

No, no, no. So for the full year, well I mean for Q1, of course, we have triple-digit numbers, but for the full year. Just to be clear, we're expecting the operating margin to expand about 60 to 70 basis points if we exclude the impact of currency. So currency will be favorable to operating profit, but it will actually have a negative impact on the margin and that negative impact will probably be in the range of 20 basis points, but then just to link it back to your comment about what we were saying before, we were saying before that we will be a little bit below our typical guide of 70 to 100 in terms of our mid-term expectations. So we might be slightly lower, but we're a little bit more optimistic just given the higher sales volume as well in terms of what we would expect and I think the other thing that always remind of -- remember is, we did 130 basis points this year. So now when we're looking at the two-year combined growth, we're probably in the 190 to 200 basis point expansion excluding currency, which we feel really good about and as we made it -- mentioned in the comments before, we feel like there's really excellent momentum on all the different margin expansion initiatives, whether it'd be pricing our SternDrive, etc.

Vijay Kumar -- Evercore ISI -- Analyst

Understood. Thanks guys.

Shawn Vadala -- Chief Financial Officer

Yeah, thank you.

Operator

Your next question comes from the line of Patrick Donnelly with Citi.

Patrick Donnelly -- Citi -- Analyst

Thanks guys. Olivier, maybe just one on the Core Industrial side, you certainly proved a lot more resilient than we expected. It sounds like maybe you expected as well. Can you just pull back the curtain a little bit in terms of what you saw in 4Q. And then also the expectations going forward. Again, kind of held in there a lot better, particularly in the developed markets, than we would have expected. So we'd love a bit more color on the performance, and the expectations as we go through '21 here.

Olivier A. Filliol -- Chief Executive Officer

Hey. Yes, our expectation was that our Industrial business would be more exposed to the slowdown of the economy. I am very pleased to see how Q4 came together across the globe, pretty much, and also across the different product lines in Industrial and I expect this will continue on to be relatively healthy. But of course, that in the second part of the year, then comparisons might and also play a game and certainly also China where of course we have this very significant Industrial business.

I would attribute it to little bit the same things that we see for the whole group that we early on did go for the pockets of growth that still exist in this market, redirecting our resources and our attention to the most attractive accounts, and that played well. There are Industry segments that are very healthy at this stage. The whole pharma production, there is Transport and Logistics that is healthy for us, and many other sub segments and in combination with the sales force guidance topic that i raised before offered really good opportunities in spite that the overall economy is challenging. So there are segments that are down for us and other segments that went nicely up and it is really up to us to focus on the right ones.

Patrick Donnelly -- Citi -- Analyst

Yeah, understood. And then maybe in response to the last question, seems like you kind of acknowledged there's potentially some upside to the revenue guidance, maybe taking in more status quo and then much of a recovery. I guess when you think about that 5 to 7 for '21, when you look at it, what do you think are kind of the one or two segments that had the most upside in terms of a lever to, if you end up beating that number. Where do you think the most conservatism is in your projection, when you go through the numbers there. You're projection when you go through the numbers there.

Olivier A. Filliol -- Chief Executive Officer

I wouldn't talk about conservatives. I think it's -- we recognize that there are industry segments with good upsides and others that will be more difficult. At this stage, we would extrapolate kind of the trends that we have seen, also in recent months where we say biopharma is strong and poke -- certain chemical sub-segments are strong. And that should remain that way. Then I would expect that in the second part of the year, we're going to see good growth in a PI pent-up demand, as we mentioned before, but then on the flip side, you have of course the comparison topics. So China will, for example, be rather down in this area -- they'll not be not the same growth rate in the second part of the year. So that's a bit.

In terms of where we might experience positive or, hopefully, not negative surprises, Product Inspection and China are certainly the ones that are -- that have potential in both directions.

Patrick Donnelly -- Citi -- Analyst

Understood. Thanks, Olivier. I appreciate it.

Operator

Your next question comes from the line of Dan Arias with Stifel.

Danial Arias -- Stifel Nicolaus and Company, Inc. -- Analyst

Afternoon, guys. Thank you. Shawn, just to follow-up on Tycho's question on Product Inspection and then some of the comments that Olivier just made there. I think the comp in PI gets 8 points easier for you guys next quarter than it was here in 4Q. So I certainly appreciate Olivier's point on maybe some of the pent-up demand driving up, but I think you said up 5% this quarter, is there a reason why you wouldn't get the high singles, maybe even low doubles in 1Q in Product Inspection?

Shawn Vadala -- Chief Financial Officer

So. Hey, Dan. Just to clarify, so for Q4 Product Inspection was down 5%. It wasn't up 5%, it was down 5%.

Danial Arias -- Stifel Nicolaus and Company, Inc. -- Analyst

Yes. Okay.

Shawn Vadala -- Chief Financial Officer

Yes. So that probably helps a little bit and but you're right, it does have an easier comparison in Q1, but as we kind of look at Product Inspection, this continues to be the one business in the portfolio that's been the most negatively impacted by COVID in high case counts and as Olivier was describing earlier, these customers really are operationally distracted at the moment. We do think that there is a really great opportunity for pent-up demand at some point, that the timing of course is just very difficult to predict at this point in time. But when we look at the guidance, mid-single digit is kind of what we're looking at for Q1, and mid-single digit is kind of what we're looking at for the full year.

Danial Arias -- Stifel Nicolaus and Company, Inc. -- Analyst

Okay, very good. Thanks for the clarification there.

Shawn Vadala -- Chief Financial Officer

Yes. No problem.

Danial Arias -- Stifel Nicolaus and Company, Inc. -- Analyst

Olivier, on your point on new product launches. If I think back to the last time you guys actually held a site visit down in Tampa, it seems like a long time ago, we were focused on the PI business obviously just given where we were, but you guys talked a lot about what you were doing in terms of product development for biopharma. Do you feel like 2020 was a year where you saw some traction there, just given the things that you were doing or should we think about 2021 kind of being the year that 2020 could have been, just given the pandemic related headwinds and also the fact that it sounds like some of the launches this year are pointing in that direction?

Olivier A. Filliol -- Chief Executive Officer

Yeah, I don't want to overstate the impact of our product launches on the topline. We often talked. We -- our strategy is to continuously upgrade and launch new product, and they add up, but I would say from one year to an order there is not that much different. Of course, the products that we showed to you in Tampa, this were particular also products in the area of AutoChem. These products are going very well, very happy with the adoption rates. They will also continue to contribute very well this year, but they are in all audited categories being it Process Analytics, being in Industrial. I talked before about lab balances and all the moments I talked in the analytical space about new products we had for UV rays, it is, for example, and so and so. This is at the whole portfolio that makes the difference to keep the technology leadership, but it's a continued thing and again last year or also 2021, I wouldn't highlight a particular product that will make the big difference to the top line.

Danial Arias -- Stifel Nicolaus and Company, Inc. -- Analyst

Okay. Thanks very much.

Operator

Your next question comes from the line of Steve Beuchaw with Wolfe Research.

Steve Beuchaw -- Wolfe Research -- Analyst

Hi, good afternoon. Thanks for bringing me on here. I wonder if I could spend a little time just trying to understand more deeply, Olivier, how it is you think the operating environment evolves around COVID over the balance of the year. Just so we have as much context as we can for your planning assumptions. I do -- sorry, I hated sorry to put words in your mouth, but my sense is that you think that in the back half of the year, there will still be some amount of macro-economic pressure, maybe there is a lingering impact of the virus into the macro is a little tougher, but that's part one. Part two is, it also seems like you think that into some of the life sciences categories, maybe around pharma, but you had some good tailwinds in that there is also maybe sort of taper off in the back half of the year. I just want to make sure I'm understanding that correctly. Is that a fair characterization?

Olivier A. Filliol -- Chief Executive Officer

Hesitate here. Just You're right, we are cautious about the macro environment for -- also for the rest of the year. I don't think the macro environment will just immediately improve when the lockdowns go away. I think there are too many drivers for our macro environment and until we have not particularly forecasted here on an improved macro environment, we more or less assume things remain about what they are today. So don't know. I wouldn't say this is particular cautious. I think we just don't know if all these industry segments that are today down will certainly recover. I would think that the momentum that we see in the industry segments like in bioproduction, I don't think it goes necessarily, away in the second part of the year. I think that can be actually quite sustainable. Yes, we had modest benefit from investments in vaccine production, but we are -- in terms of share of our total revenue remained very small. So if that would slow down, that wouldn't necessarily have a big impact on us. The investment in pharma production, and particularly, also bioproduction, I think has a long way to go. So in essence, I feel like the current macro environment that we have could last for quite a few more quarters, including the industry mix.

Steve Beuchaw -- Wolfe Research -- Analyst

Okay. That was extremely helpful. Thank you for that perspective. I've got one more follow-up to ask. Before I ask it. I know it's too soon to say goodbye to Olivier. But I am going to say hello to Patrick. It's good to hear your voice again after a little while.

Patrick Kaltenbach -- Chief Executive Officer Designate

Thanks, Steve.

Steve Beuchaw -- Wolfe Research -- Analyst

Thank you for being on the call here.

Patrick Kaltenbach -- Chief Executive Officer Designate

Thanks, Steve.

Steve Beuchaw -- Wolfe Research -- Analyst

The question I would leave with is sort of a follow-up to one that was asked earlier. There was a question asked, which frankly I would've liked to have ask too, about market share gains, and the success of what you've done in this operating environment where some of your nimble approaches really pay off in a unique way. I wonder if, maybe we could just zoom in though, maybe talk about it, particularly, as it relates to service where your ability to get people in the field in an appropriate way, of course, and in the right place might be particularly helpful. Can you talk at all about the extent to which you might see service attach rates or service relationships evolving during the pandemic environment? And then, sorry, after some very long worded questions. I'll get back in queue. Thank you.

Olivier A. Filliol -- Chief Executive Officer

On the service side here. I would say this is more an operational positive very early on. We were extremely far off in making sure that we equip our service technicians with all the safety gears. We, very early on, made sure that our customers knew about that and then we keep really operations going. You will recall what we -- when we talked about Q2, how we did many good things to maintain production going. We were one of the first ones that resumed production also China and similar things that we did also for the service technicians. So we were really up and running and what we benefit -- continue to benefit from, is we do this Net Promoter Score and we had a very nice jump in customer satisfaction in Q2 that we saw in our way and yes, it went on throughout the year. And I feel this gives tribute to really our service force how well they're performing. Having 3,000 people in the field here is powerful. Then you need also to know that for service, our biggest competition are local, I would almost say, family owned companies, and for these companies it is much more difficult to operate in the current COVID environment than for us where we have a global organization and we have a lot of professional support, plus the field force. That's one, and the second one, our efforts to migrate to contract-based service was very beneficial so that protects a lot of our a business.

Operator

Your next question comes from the line of Brandon Couillard with Jefferies. Brandon Couillard, your line is open.

Brandon Couillard -- Jefferies -- Analyst

Here we are, thanks. Shawn, more for you, on the working capital front, DSOs continue to trend lower. You talked about applying some Analytics and better productivity tools, which I think are new. I may be wrong, but are you finding new ways to apply these in that area and how much more room do you think is left there?

Shawn Vadala -- Chief Financial Officer

Yeah, no. Hey, thanks Brandon. Thanks for the question. These are new tools and so kind of happy to be able to respond to it. So, like many other things in the Company, I think it's just a really good example of agility. So back in March, we really launched into a variety of crisis management initiatives around COVID and then one of those initiatives of course was manage for cash. That what we refer to it as internally and so within that initiative, we challenged ourselves to come up with some new analytics, but even more importantly to try to make the connection between the analytics and the actions to be more efficient. So we literally are broadcasting today individual KPI charge that are highly actionable. With like top ten list as well on a very daily basis to each finance organization, going to the leader every single day, and we found that that in itself has become very actionable and it's allowed them to work with their local management teams and really get people behind areas for improvement. And so that's just one example, we've done a lot of other things in the manage for cash initiatives during the course of the year. In terms of more legs, we'll see, I think we just hit another good milestone, but when I take a step back. I think the best way to look at it is that our free cash flow conversion this year was over 100%. When we look at next year, we will probably be right around 100% again. And so I think this is a level that I don't think it's going to get too much more than 100%, but I just think that flow through around 100% is a good range. I'm comfortable looking at that for 2021 and I think as we go out, we'll take it on a year-by-year basis, but right now, we feel really good about the cash flow conversion.

Brandon Couillard -- Jefferies -- Analyst

Great, that's it for me. Thank you.

Operator

Your next question comes from the line of Jack Meehan with Nephron Research.

Jack Meehan -- Nephron Research

Thanks, good afternoon. First one for Shawn. I was just wondering if you could walk us through the different factors that led to the EPS guidance raise for 2021 at this point. I think I caught China, pricing, FX and tax rate, what did I miss?

Shawn Vadala -- Chief Financial Officer

Yes. So. Hey, probably even bigger picture, Jack. So we have increased sales overall for the Group. So that's not just China, that's just the overall Group. The next thing I would say is that we would have -- probably within that, yes, you have China being a little bit better. You have Europe being a little bit better. You have Core Industrial being a little bit better and you have Lab being a little bit better. And then we have the second thing would be our 2020 B, you have a more favorable currency environment and then of course we have the reduced tax rate. And so when you add that all up, I think that's how you bridge our guidance.

Jack Meehan -- Nephron Research

Great, thanks for walking through that. And then, just one on Food Retail. So, saw a nice little rebound in the second half of the year, but I was just wondering if maybe that was some deferred sales from earlier in the year and if your thoughts have changed it all around the outlook for 2021 there?

Shawn Vadala -- Chief Financial Officer

No, we still look at Food Retail as a low-single digit business for 2021. The business always can be a little bit lumpy. We're very much tied to customer projects and buying cycles. So I wouldn't necessarily read anything particular into the fourth quarter results, although I would say that we are looking at a more favorable outlook again in the first quarter and probably we will start the year more high-single digit there.

Jack Meehan -- Nephron Research

Great. Thanks a ton.

Shawn Vadala -- Chief Financial Officer

Yeah, welcome.

Operator

Your next question comes from the line of Dan Brennan with UBS.

Daniel Brennan -- UBS

Great, thank you. Thanks for the questions. Hoping just to dig in a little bit on Lab. I know you've talked about a lot of the initiatives there, but it was a nice beat in the quarter. So I'm just wondering if you could just flush out like how would you prioritize, what the biggest reasons we're for the upside. And for 2021, I think previously you were thinking mid-single, high-single, is that still the case or it sounds like it's kind of ticked up a little bit, maybe you can just walk us through a little bit of Lab drivers.

Shawn Vadala -- Chief Financial Officer

Yeah, hey, so. Hey, maybe I'll start with the last part of the question, Dan, so, yes, we're thinking high single-digit for for Lab for the full year for 2021 and then for Q1 we're looking at low-teens. In terms of the results in Q4, we really felt good about the whole portfolio. I mean of course the pipette business is, of course, continuing to do well. We probably had a little bit better in terms of the COVID tailwinds in terms of what we were expecting, but there was a -- but if I look at the other categories like process Analytics had a great quarter and we also did really well in our Analytical Instrument business as well as our Laboratory Balance business. So we feel like generally there is just really good momentum there globally, good market trends, of course, there are also pockets of challenge in other industries, but in particular, biopharma, is doing very well.

Daniel Brennan -- UBS

Great, thank you. And then just a second one. With some product Inspection, just given the delayed spending cycle that's ongoing here like how much pent-up demand is there, like any food manufacturers put this stuff off, is there going to be a big catch up. So how do we think about Product Inspection that you talked about a nice recovery in the second half, but then what happens beyond that, just any color on that would be helpful.

Olivier A. Filliol -- Chief Executive Officer

That's probably quite difficult to quantify, but a little bit, way to see, we have now a few quarters of decline. I would expect that we can catch up quite a bit of this, the big question will be how fast and is it going to be at the same time in the U.S., as in Europe or not, there might be also differences by industry segments. For example, the meat industry in U.S. has been very much impacted by COVID. Certainly, an area where there was very little investment or activities. So hopefully. that will come back not too far away. But then to be seen. So internally, I would say we count on the second part of the year, we were just talking also today with people from the industry. They were kind of hinting to us that the decision making might really starts to ramp up again in Q3 at customers. So that would, yes, support our hypothesis. It should go on then into next year. I would certainly hope that 2022 has also some good PI quarters.

Analyst

Great. Thanks, Olivier.

Operator

Your next question comes from the line of Steve Willoughby with Cleveland Research.

Steve Willoughby -- Cleveland Research -- Analyst

Hi, everyone. All my questions -- most of my questions have been asked already, but I just wanted to touch on one as it relates to pipettes. I believe you have some new capacity coming online this year for pipettes. So I was just wondering, given the demand you're seeing these days, where you stand today in terms of being able to meet the demand that you're seeing? And any comments on if you're seeing sort of like backlogs, or order books get extended? And what that new capacity means for your pipette business?

Olivier A. Filliol -- Chief Executive Officer

So at this stage we cannot fully satisfy the demand. We have capacity issues. This is around pips, so not on pipettes, but mainly on pips. The pips are used in COVID testing. We do expect that this is something that we have a a spike right now and will then flatten or go back. We do already extraordinary efforts to increase the capacity. We have increased the capacity in Q4 and will continue to increase in Q1.

In the summer, indeed, we have an additional facility in Mexico, our new facility in Mexico. That will go online, but it, of course will also take a few weeks that we can fully leverage that. That will bring additional capacity, but most important is that we can maximize capacity here in these days, in these weeks. It's commercially attractive, but of course, it has also relevance, it's our contribution also to help situation in the society. And so the teams are very motivated here to do the utmost.

Steve Willoughby -- Cleveland Research -- Analyst

Thanks very much. Your next question comes from the line of Matt Sykes with Goldman Sachs.

Matthew Sykes -- Goldman Sachs Group, Inc. -- Analyst

Thanks for taking my question. I'll be quick. I just have one. Just -- Olivier, you mentioned on SternDrive that if you do the challenges that you face in 2020, you might not have gotten as much of the program as you historically have. I'm just wondering are there particular cost savings projects that you have kind of lined up that we should expect some momentum, in terms of cost take-outs as we move to 2021?

Olivier A. Filliol -- Chief Executive Officer

Yes. SternDrive is about -- really dozens if not even hundreds of projects. Actually last year, I think we were working on 300 projects and just due to COVID, we had to put on hold or had some delays on a part of the 300 projects, we will resume the full speed on them here in 2021. The result in 2020 were still good and I still also expect good contribution in 2021, but a, the programs have proven to be very powerful. I'm extremely happy about SternDrive and wouldn't be surprised if down the road, SternDrive could have even a bigger impact. And I certainly also see Patrick to be passionate about the topic. He had his first review meetings around SternDrive and came back in a very positive manner about it and he will certainly engage on this and that will give the team and even more momentum. So you're going to continue to see us talking about SternDrive and having benefit from it.

Matthew Sykes -- Goldman Sachs Group, Inc. -- Analyst

Great, thanks. Very helpful.

Operator

[Operator Instructions] At this time, I would like to turn the call back over to the company for any closing comments.

Olivier A. Filliol -- Chief Executive Officer

Yeah. Thank you. Hey. Let me end this call with a simple thank you to you, analysts, and shareholders listening here on this call. Thank you for your support and commitment to Mettler-Toledo over the many years. I have truly appreciated your engagement and regal you brought to our various interactions during this time. While my focus over the next two months is successful hand over to Patrick and still delivering a very strong Q1, but I am also very happy to remain involved with Mettler-Toledo in the future through my both role as well as supporting Patrick on marketing and auto-organizational manners. I wish you all a very successful 2021. And again, a big thank you, and all the best to you. Bye-bye, everybody.

Shawn Vadala -- Chief Financial Officer

Bye-bye.

Operator

[Operator Closing Remarks].

Duration: 76 minutes

Call participants:

Mary T. Finnegan -- Head of Investor Relations

Olivier A. Filliol -- Chief Executive Officer

Patrick Kaltenbach -- Chief Executive Officer Designate

Shawn Vadala -- Chief Financial Officer

Tycho Peterson -- JPMorgan -- Analyst

Derik de Bruin -- Bank America -- Analyst

Vijay Kumar -- Evercore ISI -- Analyst

Patrick Donnelly -- Citi -- Analyst

Danial Arias -- Stifel Nicolaus and Company, Inc. -- Analyst

Steve Beuchaw -- Wolfe Research -- Analyst

Brandon Couillard -- Jefferies -- Analyst

Jack Meehan -- Nephron Research

Daniel Brennan -- UBS

Analyst

Steve Willoughby -- Cleveland Research -- Analyst

Matthew Sykes -- Goldman Sachs Group, Inc. -- Analyst

More MTD analysis

All earnings call transcripts

AlphaStreet Logo

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Mettler-Toledo International Inc. Stock Quote
Mettler-Toledo International Inc.
MTD
$1,317.20 (4.67%) $58.73

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
344%
 
S&P 500 Returns
120%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.